Marshall Wace, LLP Iveric Bio, Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $14.1 Million - $21.3 Million	536,361 Added 765.16%	606,459 $23.9 Million
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $1.31 Million - $1.72 Million	70,098 New	70,098 $1.71 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $1.25 Million - $2.59 Million	136,875 New	136,875 $1.32 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $13,765 - $19,068	-1,133 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $460,068 - $624,735	-33,266 Reduced 96.71%	1,133 $18,000

Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $243,200 - $601,982	34,399 New	34,399 $559,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.